This event will explore the rapidly evolving diagnostic and treatment landscapes of cholangiocarcinoma and hear how advances in these areas can unlock better patient outcomes.

TOPICS COVERED

We will cover the significance of identifying new genetic targets in cholangiocarcinoma and consider how best to overcome the challenges associated with molecular profiling of these patients.

WHO SHOULD ATTEND?

• Molecular pathologists and histopathologists who work in HPB specialist teams

SPEAKERS

• Prof John Bridgewater, Consultant Oncologist, University College Hospital London,
• Dr Mike Hubank, Head of Clinical Genomics at The Royal Marsden, and Scientific Director of the North London Genomic Laboratory Hub

For more information, please contact: [email protected]